Cancer vaccine - Immune Response

Drug Profile

Cancer vaccine - Immune Response

Alternative Names: GM-CSF cancer vaccine - Immune Response; mbGM-CSF cancer vaccine - Immune Response

Latest Information Update: 09 Nov 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immune Response Corporation
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Colorectal cancer; Malignant melanoma

Most Recent Events

  • 31 Dec 2003 Discontinued - Preclinical for Colorectal cancer in USA (unspecified route)
  • 31 Dec 2003 Discontinued - Preclinical for Malignant melanoma in USA (unspecified route)
  • 04 Apr 2003 No development reported - Preclinical for Colorectal cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top